|
|
Article: U.S. Patent Disclosures.
- Article from:
- BIOWORLD Today
- Article date:
- July 7, 2006
CopyrightCOPYRIGHT 2006 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Alnylam Pharmaceuticals Inc., of Cambridge, Mass., received U.S. Patent No. 7,056,704, which broadly covers methods of making small interfering RNAs. The patent, part of the Tuschl II series, was licensed from the Max Planck Society.
Ambrilia Biopharma Inc., of Montreal, received U.S. Patent No. 7,053,058, covering the signal transduction inhibitor PCK3145 and related sequences. PCK3145 is Ambrilia's lead drug for advanced metastatic prostate cancer.
Aphios Corp., of Woburn, Mass., was awarded U.S. Patent No. 7,037,534 B2 for chemiluminescence-activated antiviral therapeutics.
AVI BioPharma Inc., of Portland, Ore., received a notice of ...